Introduction 42 43
Organoids, such as vascularized organoids or spheroids 1-3 , are three-dimensional 44 multicellular clusters which mimic the structure and function of native tissues and are useful 45 for on-chip drug screening 4,5 . For use as a cell therapy, delivery of cells within well-46 controlled microenvironments, rather than suspensions of isolated cells, could promote and 47 maintain desired cellular functions within dynamic and complex in vivo environments 6-11 . 48 As organoids are increasingly being explored for in vivo studies and therapy, there is 49 increasing recognition of the unmet challenge in generating multicellular aggregates with 50 high reproducibility and control. As one example, even though control over "organoid size, 51 shape, cellular composition and 3D architecture...is essential in order to understand the 52 mechanisms that underlie organoid development in normal and pathological situations, and to 53 use them as targets for manipulation or drug testing", reproducibility has been cited as "the 54 major bottleneck of current organoid systems" 12 . 55
56
The major current methods for generating organoids include spinner cultures 13 , 57 hanging drops 14, 15 , and non-adhesive 96-well plates [16] [17] [18] [19] (Supplementary Table 1 ), but these 58 methods are difficult to scale or harsh to cells. (Alternatively, microtissues that are "cells in 59 gels" 20-23 typically feature cells moving to pre-formed pores within a hydrogel scaffold, but 60 the cells are limited in their ability to self-organize into desired structures 24 , and the resultant 61 gels exhibit variable structures and sizes dependent on the pores and may be undesired in the 62 implanted site due to potential immunogenicity). More recently, methods to fabricate 63 organoids based on micro-sized wells have faced challenges of either high adsorption (of 64 steroid hormones, small molecules, and drugs 25,26 for PDMS-based wells) or inefficient and harsh processes, usually involving vigorous pipetting or high-speed centrifugation, to 66 separate and remove the cellular clusters from the microwells. Such procedures produce 67 cellular clusters at a low yield and could damage cellular structures and function. 68
Recognizing this limitation, other studies have proposed more complex methods to actively 69 release cellular clusters from microwells [27] [28] [29] . As such, there still lacks reliable methods to 70 generate organoids at high yield and with reproducibility and control over aggregate size and 71 cellular organization. 72 73 Many hydrogels are biocompatible and have been used as a dynamically responsive 74 biomaterial (such as microfluidic valve 30 , changing cellular microenvironment 31 , and 75 stimuli-responsive drug release 32 ). We hypothesize that a dynamic change in the cross-76 linking state of hydrogels could gently release organoids, and sought to demonstrate the 77 strategy for producing large numbers of vascularized organoids with high reproducibility and 78 scalability, as well as the ability to retain functionality after passing through needles to 79 obviate invasive surgery 33, 34 . We also assessed the ability of the pre-formed blood-vessel 80 units, after injection, to rapidly integrate with the host's vascular network in a healthy mouse 81 model. 82 To cellular structures, some hydrogels (such as agarose or poly(ethylene)glycol as previously 91 demonstrated) can be non-adhesive and thereby promote cells to interact with one another 92 and contract into microtissues and organoids 1, 35 . We hypothesized that a dynamic change in 93 the cross-linking state of alginate, which can be achieved by adding calcium or a chelator and 94 has been demonstrated for other purposes 31, 36 . could similarly release cell-based structures 95 from a surface without significantly disrupting the organoid structures or underlying cell 96 function 37, 38 . Specifically, we deposit the sacrificial material, create the sacrificial structure 97 by cross-linking the alginate in its patterned state, deposit cells on top to allow cellular self-98 organization to take place, and remove the sacrificial layer by adding a chelator (5% w/v 99 sodium citrate) ( Fig. 1a ; see Supplementary Figure 1 for fabrication details). The alginate is 100 uncrosslinked within ~12 minutes ( Fig. 1b) , to gently release a large number of organoids 101 floating in solution ( Fig. 1c,d ; Supplementary Video 1). The resulting organoid solution 102 could be gently pipetted into tubes, centrifuged and resuspended in a culture medium suitable 103 for downstream manipulation or direct cell delivery. Each step is simple, can be conducted 104 with sterile liquid handling, and can be automated. 105
106
The step of cellular self-organization can be adjusted depending on the organoid of 107 interest. For vascularized organoids ( Fig. 1c ), we seeded a co-culture containing ECs and 108
MSCs (of either mouse or human origin) into the dissolvable alginate microwells. We 109 cultured the cells in media without growth factors ("maintenance" medium), followed by a 110 vasculogenic medium with growth factors to induce cell-cell interactions including sprouting 111 of blood vessel-like structures. The organoids, now containing blood vessel-like structures, 112 contract and are gently released by dissolving the alginate microwells. 113
114
The same small number of steps ( Fig. 1c, d) can harvest a large number of organoids 115 by using alginate templates with large numbers of microwells. As an example, we 116 demonstrated three different sizes of alginate microwell inserts for culture dishes ( Fig. 2a ): 117 15.6 mm-diameter inserts containing >1000 microwells (yielding >24,000 organoids on a 24-118 well plate), 22.1-mm inserts containing >3000 microwells (yielding >36,000 organoids on a 119 12-well plate), and a 60-mm diameter insert containing >30,000 microwells in a 60-mm 120 culture dish. If desired, the inserts can be stacked to increase the number of organoids 121 produced in the same area with additional media changes. 122
123
We demonstrated this massive parallel production of more than 30,000 organoids by 124 seeding a quarter of a billion cells ( Fig. 2b ) in one 60-mm dish insert ( Fig. 2c ). We also 125 tested the ability of the organoids to assemble in vitro into a microvascular network ( Fig. 2d ). 126
We co-cultured RFP-labelled MSCs and GFP-labelled ECs for four days, gently harvested 127 the organoids, and assembled them into a macroscopic tissue with surface area of 1 cm 2 and a 128 height of 1 mm ( Fig. 2d ). We performed fluorescence imaging of this macroscopic tissue 129 distributed alongside RFP-labelled mouse MSCs, migrate to the center of the organoids and 140 form endothelial cores after culture in the "maintenance" medium for 3 days (Fig. 3a , top 141 panel, and Supplementary Video 2). Similarly, ECs also formed endothelial cores when co-142 cultured with another cell type (fibroblasts) in a medium without growth factors 143 ( Supplementary Figure 2) , the endothelial cores were more pronounced than in a previous 144 observation 19 . By contrast, ECs did not migrate to the center when the organoids were 145 initially cultured in a vasculogenic medium containing 50 ng/mL VEGF and 50 ng/mL bFGF 146 ( Fig. 3a , bottom panel), consistent with a previous observation 9 . Overall, the data showed 147 the organoids to exhibit reproducible internal architectures containing endothelial cores. 148
149
We characterized the reproducibility of the method in controlling the size of the pre-150 vascularized organoid. By varying the microwell sizes and the co-culture ratios of cell types 151 ( Fig. 3b ), we controlled the number of cells that could aggregate into a single organoid. For 152 example, microwells of three different sizes (100, 200, and 400 µm diameter) yielded 153 organoids of three different sizes (39±3 µm, 71±5 µm, and 82±7 µm diameter, respectively, 154 all at the same cell-seeding concentration) ( Fig. 3b ). The well size was chosen to be large 155 enough to hold all the cells at the initial seeding concentration, but small enough to ensure 156 sufficient cell-cell contact to form a single organoid rather than multiple organoids. The cells 157 aggregated into compact organoids within the first two days of in vitro culture, as seen by the 158 decreasing radius of the smallest circle to include all cells ( Fig. 3c) , with the main contraction 159 happening in the first day and no further contraction after three days. We also observed that 160 the size of the fully contracted organoids (at day 2 and after) correlated to the number of cells 161 in the organoid as expected; the diameter of the organoids' cross sections related to the 162 number of cells in the organoid and the cells typical volume as r organoid = (6/π v cell n cell ) 1/3 /2 163 (Supplementary Figure 3) . 164 165 Also, we quantitatively analyzed the formation of organoids for cultures containing 166 only MSCs, and co-cultures with EC:MSC ratios of 1:3, 1:1, and 3:1 ( Fig. 3b-e ). In 200-µm 167 microwells, over three days, cells contracted into an organoid and ECs migrated towards the 168 center ( Fig. 3c) , and co-cultures in 400 µm microwells showed similar trends in organoid 169 contraction and EC migration ( Supplementary Figure 4 ). Co-cultures in 100-µm microwells, 170 however, did not contain enough cells (fewer than 150 cells in total) to form a distinct center 171 (Supplementary Figure 5 ). We also observed that the organoids per unit area and the number 172 of organoids containing defined internal architectures could be controlled by varying 173 microwell sizes and ratios of cell types ( Fig. 3e ). (In subsequent in vivo studies, we have 174 used 200-µm microwells with ratios of MSC only, 1 EC:3 MSC and 1 EC:1 MSC, as these 175 conditions showed aggregation involving almost all the cells within the microwells.) Overall, 176 the data showed the method can produce organoids with internal architectures at high 177 throughput and different sizes controllably. 178 179 Production of pre-vascularized human organoids with reproducible size and structure 180
181
We examined the effectiveness of this method for producing pre-vascularized 182 organoids containing human adipose-derived MSCs (hAMSCs) with human umbilical vein 183 endothelial cells (HUVECs), in ratios of MSCs only, 1 EC:3 MSC, and 1 EC:1 MSC. We 184 examined the maturation of organoids over 8 days, where organoids were first grown in 185 maintenance medium over 3 days to form endothelial cores, and then switched to 186 vasculogenic medium containing exogenous growth factors for 5 days (Fig. 4a ). By day 8, 187
vessel-like structures, such as lumens within the center of the organoid, with sprouting and 188 maturation of vessels towards the surface were observed (especially evident in the larger 189 organoids of the 400-µm wells). The initial migration of ECs was apparent after 20 hours 190 ( Fig. 4b and Supplementary Figure 6 ). In addition, we placed multiple pre-vascularized 191 organoids inside 400 µm alginate wells that were collagen-doped, to mimic the adhesiveness 192 of native tissues. Within 24 hours, organoids attached to each other and contracted to form a 193 larger, compact mesotissue (aggregation of multiple organoids) with a smooth outer border 194 Next, we assessed the effectiveness of the prevascularized organoids to self-organize 202 to form a vascular network, anastomose to native host vasculature, and be perfused with host 203 blood in a mouse model ( Fig. 5a ). To facilitate real-time visualization, we performed surgery 204 to place a window chamber (Supplementary Figure 8 ) to permit brightfield, epifluorescence 205 and confocal imaging. We used organoids formed in 200-µm wells yielding organoids 206 approximately 70 µm in diameter, which is also within the diffusion limit of oxygen 39 . We 207 produced and harvested pre-vascularized organoids made of human cells (HUVECs and 208 hAMSCs), which we injected into SCID mice, a well-established animal model for studying 209 integration of xenografts made of human cells 40 . We could inject and monitor the vascular 210 formation for multiple different conditions (e.g. 1 HUVEC : 1 hAMSC and hAMSC only) in 211 the same mouse, by utilizing the strong bond between the fascia and the subdermis. We 212 injected the organoids through the fascia and into the space between the fascia and the 213 subdermis, leaving the subcutaneous tissue intact between injection sites to create a barrier showed rapid vascularization of the injected organoids. 233
234
We also explored whether this self-organizing, "micro-to-macro" strategy could 235 provide a limited but reproducible level of architectural control in the overall branching 236 length of implanted, perfused microvasculature. Specifically, we hypothesized that average 237 distances between endothelial cores could be related to diameters of organoids. The mean 238 length of the perfused branches for 1 EC:1 MSC at day 7 was 93±39 µm, with minimal 239 changes by day 9 to 11, when the mean branch length was 86±29 µm and 93±44 µm, 240 respectively ( Fig. 5d ). Indeed, the length of the newly formed vasculature's branches 241 reflected core-to-core distances between the densely packed, injected organoids with 242 diameters of 71±5 µm. 243
244
We also used epiflourescence and confocal microscopy to characterize the formation 245 and integration of the new vasculature. Observing the GFP-labeled HUVECs through the 246 window chamber (Fig. 5e ), we noticed the endothelial cores connecting with each other over 247 time: the ECs initially appeared as discrete cores (day 0), then sprouted toward neighboring 248 cores (day 4), connected with the host vasculature and became perfused (day 7), and 249 stabilized as the perfused vascular network matured (day 9, 12, and 23). Between days 4 and 250 7, the network matured to form lumens ( Fig. 5e , red arrows). (We further confirmed the 251 lumenous structure of the newly-formed, perfused network on day 11 via confocal 252 microscopy on day 11, Supplementary Video 4.) Moreover, we observed that areas 253 indicating newly formed lumens (consisting of GFP-labelled HUVECs) co-localized with 254 areas indicating host blood perfusion, further confirming that it was the newly-formed 255 lumenous vasculature that was perfused, rather than angiogenesis from the host into the 256 implanted tissue. 257 258 Discussion 259 260
Using sacrificial hydrogels to produce organoids with high reproducibility and 261 scalability. Like the development of micromachining techniques for producing MEMS 262 structures reproducibly and on a large scale, we have developed a technique to use sacrificial 263 hydrogels to produce clusters of self-organized cell-based structures with high reproducibility 264 and scalability. Previously, we and other groups have shown the use of microfabricated 265 hydrogels, including sacrificial techniques, to form in vitro microvascular networks 31, 37, 41, 42 . 266 This paper demonstrated the dynamic structure of hydrogels can also be exploited to produce 267 and gently release organoids for cell therapy. 268
269
For purposes of cell therapy, it is critical for clinical efficacy, process control, and 270 regulatory approval that cells introduced into the body are generated via tightly controlled 271 processes and exhibit reproducible origin, size, and structure. Previous studies have observed 272 that a "lack of control over the process is likely to underpin the variability in systems and 273 experiments that, with few exceptions, does not allow [organoids] to yield their full 274 potential", and the importance of achieving reproducible "organoid size, shape, cellular 275 composition and 3D architecture" in future research on organoids as well as use for 276 therapeutic purposes 12 . Compared to current organoid systems, our method can generate 277 self-organized multicellular aggregates with both high yield ( Supplementary Table 1 ) and 278 high reproducibility over aggregate size and cellular organization ( Supplementary Table 2 ). 279
Moreover, the aggregate size and features of cellular organization can be tuned 280
( Supplementary Table 2 Also, an ideal method for generating organoids should be scalable and gentle. In the 290 common hanging-drop method, 384 organoids could be produced in the area of an overall 291 standard well plate (with the overall scalability limited by the number of wells 14 ), whereas 292 the smallest construct shown in Fig. 2 produces 24 ,000 organoids in the same area with fewer 293 steps needed (e.g. media-changing steps, one alginate dissolving step), all of which could be 294 automated by liquid handling. The release of organoids is gentle even at a large scale, in 295 contrast to vigorous pipetting or high-speed centrifugation for current microwell procedures. 296
For cell therapy, it is important that the integrity of the cells be preserved (for example, a 297 FDA guidance document points to the need "to preserve integrity and function so that the 298 products will work as they are intended" 44 . Beyond cell therapy, large-scale and effective 299 production of organoids (beyond the quarter billion cells demonstrated) could also support 300 studies in developmental biology, cancer cell intravasation 16 , and organ printing. 301 302 An advanced, controlled form of cell therapy. In past studies, needle injection (and 303 organ printing) with unilaminar vascular organoids 45,46 had been challenging due to shear 304 stress formation. It would be advantageous in cell therapy to be able to deliver the cells via 305 minimally invasive injection rather than invasive surgery. Our method produced organoids 306 which held up intact to shear stress during injections, even with high (25 to 30)-gauge 307 needles ( Supplementary Figure 9 ). This behavior may partially have been due to a shell of 308 MSCs which protected the endothelial structure; interestingly, previous studies have also 309 shown that the MSCs could act as an immune-suppressive shield for cell therapy in addition 310 to providing angiogenic signaling 47, 48 . 311 312 A potential application of these organoids is to treat peripheral artery disease, the 313 most severe form of which is critical limb ischemia (CLI) which can lead to amputations 49 . 314
To date, over 50 cell-therapy trials are at clinical stages for treating CLI. Many trials involve 315 injecting MSCs [49] [50] [51] [52] [53] or ECs (such as MarrowStim) 52,54,55 , but the cells could die from 316 deprivation of oxygen and nutrients before they are able to assemble into vascular networks 317 in vivo and anastomose with host vasculature. The use of therapeutic pre-vascularized 318 organoids could overcome many of the issues associated with currently cell therapy trials in 319 clinical trials to treat CLI. In a clinical scenario, such an approach could be especially 320 attractive for "no-option" patients on the verge of amputation with subsequently poor 321 mortality outcomes (60% within five years of surgery 49 ). 322
MATERIALS AND METHODS 324 325

Experimental design 326
The objective of this study was to develop an approach to form self-organized 327 organoids in a scaleable and gentle manner, for use as an injectable cell therapy. As 328 such, we designed dissolvable alginate microwells to culture organoids, promote self-329 organization of the cells, and gently harvest the organoids. We then demonstrated their 330 functionality in a healthy mouse model using a window chamber assay. All cells used 331 in these studies were purchased commercially, all animal procedures were approved by 332 the Columbia University Institutional Animal Care and Use Committee (IACUC) and 333 all experiments were performed in accordance with relevant guidelines/regulations. 334 335
Fabrication of alginate microwells 336
We developed an experimental setup to culture cellular organoids with high 337 throughput and without the labor-intensive hanging drop approach. We seed the cells onto an 338 alginate construct with between 379 and 30,000 microwells. The cells will settle into these 339 microwells, and as the alginate provides no adherence structure for the cells, the cells will 340 adhere strongly to each other forming spherical cell aggregates over the initial 24 hours. 341
The alginate microwells are cast on hydrophilic PDMS molds. We fabricated master 342 molds in SU-8 (SU-8 3050, Microchem, Newton, MA) on 3-inch Si wafers (Silicon Sense, 343 Nashua, NH) by photolithography as described before 38 to cast polydimethylsiloxane 344 (PDMS, Sylgard 184, Essex Brownell, Fort Wayne, IN) replicas from the masters. We then 345 made the PDMS molds hydrophilic by plasma treatment, and submerged them in distilled 346 water to retain their hydrophilicity. We then autoclaved the PDMS molds prior to casting 347 alginate.
We then prepared and autoclaved a 2% w/v alginate (Pronova UltraPure MVG, 349
NovaMatrix, Drammen, Norway) or 7.5% w/v alginate (Alginic acid sodium salt, Millipore 350
Sigma, St Louis, MO) in HEPES saline buffer solution (Ultrasaline A, Lonza, Basel, 351
Switzerland). The alginate was pipetted into the PDMS molds. We used positive- 
Uncrosslinking of sacrificial alginate 364
To determine the length of time required to uncrosslink the microwells, 7.5% w/v 365 alginate microwells were fabricated as described in the previous section, and stored in 1.8mM 366 CaCl 2 overnight. The following day, the alginate microwell scaffolds were transferred to 367 preweighed, individually cut wells (from a 24 well plate), any excess CaCl 2 was removed, 368 and the initial mass of the alginate scaffolds was measured. We then added 1 mL of PBS, 369 0.5% w/v sodium citrate, or 5% w/v sodium citrate to the well, and after 1 minute the excess 370 supernatant was removed, the remaining alginate scaffold was weighed, and a fresh solution 371 of PBS, 0.5% sodium citrate or 5% sodium citrate was added. This was repeated until the 372 alginate microwell scaffold was fully uncrosslinked (by the sodium citrate). Then the 1.8 mM CaCl 2 solution that the alginate microwells were stored in was 390 removed, and replaced with DMEM (ATCC, Manassas, VA). The microwells were then 391 placed in the incubator at 37°C and 5% CO 2 to equilibrate for at least 20 minutes. Then 392 DMEM was removed and the microwell constructs gently dried using surgical spears 393 (Braintree Scientific, Braintree, MA) leaving the microwell features covered. 394
Cell suspensions were then pipetted on to alginate molds of 100, 200 and 400 µm 395 microwell size using a positive displacement pipette. Cells were left to settle to the bottom of 396 the microwells for 20 minutes and the culture wells were then filled up with culture medium. 397
Culture media 399
The first 3-4 days after seeding, the cells were cultured in maintenance medium: 400
Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal Bovine Serum (FBS) and 1% 401
PenStrep (all from LifeTechnologies), with 50 μg/mL Sodium L-ascorbate (Sigma-Aldrich). 402
For Fig. 4 and 5, the maintenance medium also included 20 mM Hepes (Fisher Scientific, 403 LifeTechnologies), with 50 μg/mL Sodium L-ascorbate (Sigma-Aldrich), 40 ng/mL bFGF 409 and 40 ng/mL VEGF recombinant human protein (both from LifeTechnologies). For Fig. 4  410 and 5, the vasculogenic media also included 20 mM Hepes, 1 μM Insulin, and 250 nM T3. 411
The cells were cultured in vasculogenic medium up to day 11. Cell media was changed every 412 other day. 413
414
Harvesting of organoids 415
To collect organoids, the alginate hydrogel was uncrosslinked 37 . For this, the culture 416 medium of the organoids was replaced with 5%w/v sodium citrate solution for approximately 417 20 min. This chelator liquefied the alginate, and allowed for resuspension of the organoids in 418 a desired medium. Organoids were then centrifuged at 300 rpm for 5 minutes or as specified 419 and the organoid pellet carefully collected for further use. 420 421
Organoid fusion 422
To test the ability of organoids to assemble in vitro and fuse to a larger tissue, 200 μm 423 sized organoids of only hAMSCs, 1 EC : 3 hAMSC and 1 EC : 1 hAMSC ratio were placed 424 in a 400 μm sized microwell of collagen-doped alginate 38 composed of 3.5% collagen and 425 1% alginate. These organoids had previously been prevascularized as described above. 426
Organoid fusion was conducted in vasculogenic medium and observed for 24 hours. 427 428
Formation of macrotissue 429
To yield a large enough number of organoids in parallel to produce a macroscopic 430 tissue, we seeded a co-culture of 1 MSC : 1 EC ratio onto an alginate microwell construct 431 that fits into a 60 mm culture dish and produces over 30,000 organoids ( Fig. 2a and c) . The 432 cells were cultured in maintenance medium without growth factors for 4 days with daily 433 media change due to the high number of cells. The organoids were collected by removing the 434 medium and uncrosslinking the alginate with 5 mL 5%w/v sodium citrate solution. The 435 alginate liquefied and the organoid solution was gently collected, spun down and resuspended 436 in 1 mL vasculogenic media. To facilitate sustained culture and imaging of the macro-tissue, 437
we had constructed a 1 cm 2 cylindrical hole in a 1 cm thick 10% agarose layer in the middle 438 of a 60 mm dish. The hole was made by placing a 1 cm 2 by 1 cm PDMS mold in the middle, 439 pouring on agarose and removing the PDMS cylinder when the agarose had gelled. The 1 mL 440 organoid suspension was pipetted into the hole, allowed to settle for 1 hour, and then had 5 441 mL vasculogenic media added on top. The media was changed daily. 442 443 Window chamber surgery 444 Organoids were collected as described above. The suspension was gently spun down at 445 220 g for 5 minutes. The supernatant was removed and the organoids resuspended in 200 µl 446 PBS. In vitro created, prevascularized and non-prevascularized organoids were implanted in a window chamber to allow for continuous in vivo monitoring of the vascularization and 448 integration process. Window chamber surgeries were conducted as described previously 56, 57 . 449
A titanium window chamber (APJ Trading, Ventura, CA) was surgically implanted midline on 450 the dorsum of male SCID mice (strain: ICRSC-M-M, 5-6 weeks of age, Taconic, Hudson, NY) 451 after hair removal and ethanol and iodine disinfection. 452
To reduce variability between mice, prevascularized and non-prevascularized 453 organoids were implanted in individual compartments of the same window chamber. 
